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Abstract 
 
Polymorphism is not only limited to single component systems. Co-crystals have 
exhibited polymorphism and various polymorphic co-crystals have been reported. 
Polymorphism in co-crystals presents an expansion of the optimization space around 
a pharmaceutical compound and also offers the opportunity to develop novel 
patentable material. Polymorphism of pharmaceutical co-crystals was investigated by 
means of an exhaustive data mining survey and the formation of polymorphic co-
crystals. The search was performed using the Cambridge Structural Database (CSD). 
The search aimed to find and tally neutral pharmaceutical co-crystals which are 
polymorphic. The survey of the CSD showed that 14% of the pharmaceutical co-
crystals were polymorphic. The co-crystal of theophylline and 3,4-dihydroxybenzoic 
acid was found to be polymorphic and the novel polymorph was synthesized and 
characterized. The co-crystals were characterized by x-ray crystallographic 
techniques and Differential Scanning Calorimetry. The single crystals of 
carbamazepine and cinnamic acid was grown and characterized by SCXRD for the 
first time. The single crystal data was able to show that the hydrogen bonding 
packing that was modelled in the literature is incorrect.   
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1. Introduction: Solids and the 
Pharmaceutical Industry 
 
There are many drugs on the shelves of pharmacies and more are still being 
developed for multiple reasons. Of all the lead compounds that are currently under 
development, only 1% of those potential drugs will make it onto the shelves.1, 2 These 
poor laboratory-to-market turnover rates are due to many setbacks and pitfalls 
during the drug development journey. Some of the chief issues attributed to the 
discarding of a lead compound are related to the compound’s properties in the solid 
state.3 Bioavailability (highly influenced by the dissolution rate), solubility, stability 
and other physical properties are some of the troublesome properties that need to be 
optimised early in drug development in order to increase the lead compound’s 
chance of success.1  
 
1.1. The Crystalline Solid State 
The solid state comes in many forms. Understanding the difference between these 
forms is fundamental to knowing which solid form to opt for during drug 
development. Knowledge about the chosen solid form can drastically reduce the 
amount of time taken during the early drug development stage and ultimately reduce 
the costs of drug development.4 Usually, crystalline solids are targeted first because 
crystalline solids are more thermodynamically stable than their amorphous 
counterparts.4 There are many different types of crystalline materials including (but 
not limited to) salts, co-crystals and clathrates. Figure 1 gives a basic overview of 
what these crystalline solids are and how they are related.  
2 
 
   
Figure 1: Flow diagram showing the different types of crystalline solids. Adapted from Steed5 
and Aitipamula et. al. 6 
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Crystalline materials derive some of their physical properties from their molecular 
arrangement within the crystal.1 Altering the arrangement of these molecules and the 
interactions alters the physical properties of these solids.1 This principle is used 
extensively in attempts to improve properties of pharmaceuticals. Opting for 
alternative solid forms is a well-established technique in the pharmaceutical 
industry.7 These improvements can be anything from altering the melting point to 
changing the taste of the medicine.2 For example, bitter drugs can be made more 
palatable by using inclusion complexes such as β-cyclodextrin .4 These complexing 
agents are able to make drugs appear less bitter tasting by either decreasing the 
solubility of the drug upon ingestion or by weakening the drug – taste bud 
interaction. 
 
1.2. Co-Crystals  
Crystallization is known for being a method of molecular exclusion and 
recrystallizations are frequently used to purify compounds. Performing 
crystallization experiments in order to include other molecules is counter-intuitive 
and is referred to as co-crystallization which leads to what is called a multi-
component molecular complex or co-crystal.8, 9 
 In the past pharmaceutical companies have used salts to improve the active 
pharmaceutical ingredients (API) properties and as a result 50% of the medicines on 
the market are still  delivered as salts.4 Salts are chemical compounds comprising an 
assembly of cations and anions.10  Co-crystals, just like salts, can provide an 
improvement of the unfavourable properties of pharmaceuticals. Co-crystals also 
offer the additional advantages of the nullification of the ionizable centre 
requirement that is present for salt formation.2 This opens up the possibility for non-
ionizable drugs that were discarded because of poor properties, to be reformulated.  
The increase in co-crystal research has been propelled by the fact that approximately 
70-80% of the drugs currently under development are classified as Class 2 or Class 4 
by the biopharmaceutics classification system.1, 4 Class 2 drugs are compounds that 
show low solubility and high permeability (Figure 2).1, 4 Class 4 drugs are compounds 
with low solubility and low permeability.4 These compounds, particularly class 2, are 
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of interest with respect to co-crystals because a co-crystal could possible increase the 
solubility of these compounds.  
 
Figure 2: Diagram showing the different classes in the biopharmaceutics classification 
system.11 
 
1.2.1. What is a Co-crystal? 
Currently, there is no universally accepted definition of a co-crystal.6 A broad 
definition is that a co-crystal is a crystalline material with two or more different 
molecules within its crystal lattice.5, 9 This broad definition includes all multi-
component crystals such as solvates, hydrates, inclusion complexes and others; 
whether or not all these solids are indeed co-crystals in still up for debate.12, 13 To 
narrow the scope of co-crystal research, many researchers have included some 
restrictions on their definition of a co-crystals.5 These restrictions commonly include: 
i. Stoichiometric ratio of entities in the crystal;  
ii. Entities must be solid at ambient conditions.  
The first restriction excludes non-stoichiometric inclusion complexes such as urea 
channel clathrates. The second restriction excludes solvates and hydrates from the 
co-crystal definition. The trouble with restriction (ii) becomes the inherent difference 
in ambient conditions in different laboratories. These laboratories will then define 
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different compounds as co-crystals. Even though there is general intuitive consensus 
that some compounds (such as crystals of racemic compounds, which contain equal 
amounts of opposite enantiomers)5 are not co-crystals, the question of ‘what is a co-
crystal?’ remains unanswered. For this work, the definition that will be employed is 
the definition put forward by Jones14 which defines a co-crystal as “a crystalline 
complex of two or more neutral molecular constituents bound together in a crystal 
lattice through non-covalent interactions, often including hydrogen bonding.” In 
pharmaceutical co-crystals the constituents are a drug compound and another 
molecule often called a co-former. The co-formers used in pharmaceutical co-crystals 
are normally substances which are categorised  as “generally regarded as safe 
(GRAS)” as they can be used as food additives.2 
 
1.2.2. Prevalence of Co-crystals 
A study done by the company SSCI attempted to gauge the prevalence of co-crystals 
and other solid forms.5, 15 Although, the study had a small sample size, the results 
they obtained are a good indication of the prevalence of co-crystals, polymorphs and 
other solid-state forms. SSCI found that from 245 polymorph screens, 91% of the 
compounds had more than one crystal form and approximately 50% had two or more 
polymorphs. From 64 co-crystal screens, 61% of the compounds formed co-crystals 
and about one third formed solvates or hydrates. 
 
1.3. Physicochemical Properties of Co-crystals 
The allure of co-crystals is the possibility of attaining better physicochemical 
properties for troublesome compounds. The properties that are generally sought to 
be optimized are solubility, stability and bioavailability. Numerous studies have been 
performed to investigate these properties of co-crystals.16-18 
 
1.3.1. Melting Point  
The melting point of an API is related to its processability and stability. The numbers 
of studies that have been done on melting point changes induced by co-crystallization 
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are numerous. Aakeröy and co-workers19 hypothesized that the melting point of an 
API may be tuned by co-crystallization. They went on to show that the melting points 
of five co-crystals – listed in Table 1 – of the anticancer agent 
hexamethylenebisacetamide (mp:181-182°C) were directly related to the melting 
point of the dicarboxylic acid co-formers (Table 1).  In a different study, it was shown 
that the melting points of co-crystals were usually in between that of the co-former 
and the drug compound, or lower.20 The observed trend is that co-crystallization does 
in almost all cases result in crystals that have melting points that are different from 
the melting point of the pure API. 1, 19, 20 
Table 1: Melting points of co-crystals and co-formers used in study by Aakeröy and co-
workers.19 
Co-former Co-former melting point (°C) Co-crystal melting point (°C) 
Dodecanedioic acid 127-129 146-148 
Sebacic acid 131-134.5 148-150 
Suberic acid 141-144 158-160 
Adipic acid 152.1 165-167 
Succinic acid 184 186-188 
 
1.3.2. Stability 
There are studies that show that co-crystals can in some cases improve the stability 
of an API. Physical and chemical stability are important factors that highly influence 
the success of an API. Different types of solid state stability are investigated in the 
preclinical trial drug development. These include but are not limited to moisture 
sensitivity, air sensitivity and solution stability (the ability of co-crystal components 
to stay in solution and not precipitate out). The extreme moisture sensitivity of 
caffeine was improved by co-crystallization with oxalic acid.21 The caffeine·oxalic acid 
co-crystal remained stable in 98% relative humidity for seven weeks whilst the 
caffeine crystal formed the hydrate soon after exposure to 98% relative humidity. 
Another example is the 1:1 co-crystal of saccharine and adefovir depivoxil, which 
proved to possess superior chemical stability when compared with the pure drug 
substance.22, 23 The adefovir depivoxil·saccharine co-crystal stayed chemically stable 
for 29 days longer than the pure drug, which degraded to form mono-
(pivaloyloxymethyl)-9-(2-phosphonylmethoxyethyl)adenine, pivalic acid and 
7 
 
formaldehyde when heated at 60°C. Other studies have been performed with a 
variety of co-crystals that have been subjected to different conditions including 
thermal,16, 17 chemical,17 solutions and thermodynamic stability.18 
 
1.3.3. Solubility 
Co-crystals have the ability to influence the lattice energy and the solvation of the 
crystal with varying degrees of success.2 These two independent factors determine 
the solubility of the crystal. This makes the improvement of a drug’s solubility using 
co-crystallization very plausible. Class 2 and class 4 drugs both have issues with 
solubility, thus improving solubility by co-crystallization is one of the key aims of 
many co-crystal screens.4 In the case of the curcumin·resorcinol co-crystal, the 
solubility of the co-crystal was 4.7 times higher than that of the poorly soluble 
curcumin.24 An even greater solubility increase by a factor of 11.8 was reported for 
the curcumin·pyrogallol co-crystal (Table 2).  
Table 2: Amount of curcumin dissolved in 40% ethanol/water at 37°C over a period of 4 hours 
when starting from different solid-state forms.24 
Compound Amount dissolved (mg/L) 
Pure curcumin 67.620 
Curcumin·resorcinol co-crystal 111.025 
Curcumin·pyrogallol co-crystal 179.609 
 
There are many studies heralding the superiority of co-crystals and all the 
improvements that they can offer. Even though it is true that there are many cases of 
co-crystals enhancing the physicochemical properties of a drug compound, it must be 
noted that there are also cases where the co-crystallization has worsened the 
properties of the API. One such example is that of the carbamazepine co-crystals with 
highly soluble co-formers.  These co-crystals were found to be more unstable in 
water because they quickly disintegrated to form the carbamazepine dihydrate.25 So, 
even though co-crystallization can make things better it is not a one-size-fits-all 
solution for the issue of drugs with poor physicochemical properties.4 
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1.4. Designing Co-crystals: Crystal Engineering 
Crystal engineering is a branch of crystallography that applies the knowledge of 
prevalent intermolecular interactions to design organic and organometallic crystal 
structures. Targeted attempts to design functional crystal structures using 
intermolecular interactions principles fall within the realm of crystal engineering, 
although these attempts may not always work out as planned. 26 Crystal engineering 
is the approach frequently used in co-former selection for co-crystal screening.2 This 
is possible because pharmaceutical co-crystals are susceptible to design by crystal 
engineering since many APIs have multiple functional groups that can be used in 
crystal engineering endeavours.8 These targeted functional groups can usually be 
used to form strong and directional intermolecular interactions. One such functional 
group is the carboxylic acid group, which was found in 30 of the top 100 selling 
prescription drugs in the United States of America.27 This functional group is 
susceptible to hydrogen bonding and is often used in crystal engineering. 
 
1.4.1. Intermolecular Interactions 
There are many intermolecular interactions that play a crucial role in molecular 
recognition and molecular assembly.27, 28 The two most important properties of 
intermolecular interactions are their strength and directionality. The strength of the 
interaction is important since that determines the quantity of influence which that 
particular interaction has on molecular assembly.28 It must also be noted that with 
intermolecular interactions there is strength in numbers, i.e. numerous weaker 
interactions can outweigh the influence of stronger interactions. This is referred to as 
the Gulliver effect.28 The second property is directionality. Interactions which are 
more directional are of greater significance because they can be exploited to achieve 
specific and pre-desired intermolecular orientations. 
Non-directional (isotropic) intermolecular interactions are mainly of the dispersion 
and repulsion type.28 These interactions are responsible for the close packing of 
molecules to form a crystal. Some of these interactions are C···C, H···H and ionic 
interactions. Directional (anisotropic) interactions have electronic distributions that 
give rise to certain chemical attributes.28 
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The most notable intermolecular interactions are hydrogen bonds, halogen bonds 
and charge transfer interactions.8 Halogen atoms tend to interact with atoms that 
have lone pairs which results in an intermolecular interaction commonly known as 
the halogen bond.29  Recently, halogen bonds have been under the spotlight because 
halogen bonds are of moderate strength and directionality which makes them a good 
intermediate between strong and weak hydrogen bonds.30 The hydrogen bond is the 
most frequently used in supramolecular synthesis because it is a strong and 
directional interaction, making it ideal for influencing molecular assembly.3 
 
1.4.2. The Hydrogen Bond 
The IUPAC definition of a  hydrogen bond is: “an attractive interaction between a 
hydrogen atom from a molecule or a molecular fragment X–H in which X is more 
electronegative than H, and an atom or a group of atoms in the same or a different 
molecule, in which there is evidence of bond formation.” 31,32 Hydrogen bonds are 
represented as an interaction between a donor (D-H) and acceptor (A). The 
interaction is denoted with three dots between donor and acceptor (D-H···A). 
Characteristic features of the hydrogen bond – depicted in Figure 3 – are the 
hydrogen-acceptor distance (d) and the angle of the interaction ∠ D − H ∙∙∙ A (ϴ). 33 
For strong hydrogen bonding interactions, the strength of the interactions is in the 
range of 4 – 15  kcal mol-1 and the angle of the interaction tends toward 180°.34 
 
Figure 3: The hydrogen bond. The red dashed line indicates the intermolecular interaction and 
the black solid line a covalent bond. The interaction angle (∠ 𝐃 − 𝐇 ∙∙∙ 𝐀) is labelled as ϴ and the 
hydrogen∙∙∙ acceptor (H∙∙∙A) distance as d. 
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The standard “linear” hydrogen bond is shown in Figure 4a. In reality, the hydrogen 
bond angle is rarely 180° due to the spatial constraint of molecules. Also, the 
hydrogen can interact with a second acceptor (bifurcated hydrogen bond, Figure 4b). 
Very rarely is the hydrogen also seen to interact with three acceptors (trifurcated 
hydrogen bond, Figure 4c).28 Multi-furcated interactions occur in organic crystals 
when there are more acceptors than donors.28  
 
Figure 4: Different types of hydrogen bonding interactions. (a). The standard interaction with 
one acceptor. (b) Bifurcated interaction with two acceptors. (c) The trifurcated interaction with 
three acceptors. 
 
The hydrogen bond is a cooperative interaction which is more stable when associated 
with other hydrogen bonds.28 In other words, hydrogen bonds tend to aggregate in 
the form of dimers, trimers and chains.   
 
1.4.3. Supramolecular Synthons and Retrosynthesis 
Crystal engineering is synonymous with supramolecular synthesis. Supramolecular 
synthesis is analogous to covalent synthesis in organic chemistry (Figure 5). Just as 
atoms are held together by covalent bonds in covalent synthesis, molecules are 
connected by intermolecular interactions in supramolecular synthesis.  
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Figure 5: Infographic depicting supramolecular synthesis and covalent synthesis analogy. 
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In organic synthesis, the molecular synthons are ‘small structural units within 
molecules which can be formed and/or assembled by known or conceivable synthetic 
operations'26 and so following from that in supramolecular synthesis, supramolecular 
synthons are `structural units within supermolecules which can be formed and/or 
assembled by known or conceivable intermolecular interactions’.35 These structural 
units are spatial assemblies of intermolecular interactions between functional 
groups.26 These supramolecular synthons (henceforth will be referred to only as 
synthons) make up the cornerstone of supramolecular synthesis.28 Common 
synthons are functional groups cemented together with directional interactions such 
as hydrogen bonding (Scheme 1). However, not all synthons are held together by 
directional interactions. “Phenyl embraces” are patterns of triphenylmethanes and 
diphenylmethanes which are made up of C-H∙∙∙C interactions.28 
 
 
Scheme 1: Some representative supramolecular synthons. 
 
Synthons have been classified as homosynthons or  heterosynthons.28 Homosynthons 
contain the same functional groups interacting with each other (Scheme 2a) and 
heterosynthons contain different functional groups interacting with each other 
(Scheme 2b).28  
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Scheme 2: Examples of a homosynthon and a heterosynthon. (a) Carboxylic acid homosynthon. 
(b) Carboxylic acid···pyridine heterosynthon. 
 
The advantage of the synthon approach is that it provides a simplified way of 
understanding crystal structures. The approach also works best when useful 
synthons can be identified from known crystal structures.26 These synthons can be 
identified by studying known crystal structures of molecules with similar structures 
or structural moieties. The disadvantage of the synthon approach is that, even though 
the formation of a particular synthon may be favourable, it may result in a 
supermolecule which cannot pack in an ordered crystalline fashion.2 Moreover, the 
approach does not consider factors such as competition among the different 
functional groups present within the API or the co-former, nor does it consider the 
steric density around the donor and acceptor.2 
 
1.5. Polymorphism  
Polymorphism as defined by McCrone is “a solid crystalline phase of a given compound 
resulting from the possibility of at least two different arrangements of the molecules of 
that compound in the solid state” 36-39  This definition means that a given entity which 
can assemble in various patterns in the crystalline solid state is said to be 
polymorphic.  
 The high occurrence of polymorphism in APIs is attributed to their flexible 
structures.40  In the study performed by SSCI, it was found that most of the 
compounds they screened for polymorphism exhibited polymorphic behaviour.15 
From the 245 compounds screened for polymorphism, it was found that 226 
compounds had, at least, two or more polymorphs (Figure 6). 
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Figure 6: Plot showing the number of compounds that had one or more polymorphin a screen 
carried out on 245 compound by SSCI(Reproduced from Stahly).15 
 
1.5.1. Thermodynamics 
Polymorphs are categorized into two groups depending on the thermodynamic 
stability relationships between them.38 The main approaches used to assess 
thermodynamic stability are based on Burger-Ramberger rules, and energy-
temperature diagrams (Figure 7).38 The Burger-Ramberger rules distinguish between 
the two categories which are monotropic and enantiotropic. The energy -temperature 
diagrams make the calculation of transition temperature possible.  An enantiotropic 
relationship is one in which one polymorph is stable over a temperature range and 
undergoes a reversible transition into another form which is stable over a different 
temperature range.41 Polymorphs are monotropically related when one polymorph is 
the most thermodynamically stable form from 0 K  all the way up to its melting point, 
such that all other forms are metastable with respect to it.42 
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Figure 7: Energy-temperature diagrams for the enantiotropic (left) and monotropic (right) 
systems for solid phases of polymorphs A and B.41 
 
1.5.2. Polymorphism in the Pharmaceutical Industry 
It is estimated that 50% of drug molecules are polymorphic.42 This is not surprising 
since pharmaceutical companies invest large sums of money and time in rigorous 
polymorph screens.  Polymorphs of an API may have very different physicochemical 
properties this is the reason why screening for polymorphs is important in the 
pharmaceutical industry.43 Abbott Laboratories discovered this the hard way when 
they lost an estimated $250 million in sales. This occurred when the commercial form 
of the drug Norvir had to be reformulated due to the crystallization of a then 
unknown polymorph of the API, ritanovir, and the new polymorph was not as active 
as the old one.44  
 
1.5.3. Polymorphism in Co-crystals 
Polymorphism is not only limited to single component systems. Co-crystals have 
exhibited polymorphism and various polymorphic co-crystals have been reported.2 
Literature is rife with studies investigating polymorphism of single component 
crystals.45-46 In comparison, reports on polymorphism in co-crystals are not as 
ubiquitous.47 Polymorphism in co-crystals (Figure 8) presents an expansion of the 
optimization space around a pharmaceutical compound and also offers the 
opportunity to develop novel patentable material.2 The number of reported 
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polymorphic co-crystals has increased in recent years.40 Additionally, advances in 
experimental techniques have made polymorph screening less of a serendipity-
dependent affair and have paved the way for more successful screens.48 
Polymorph 1
Polymorph 2
Co-crystal 
polymorph 1
Co-crystal 
polymorph 2
Drug compound
Co-former
 
Figure 8: Diagrammatic representation of polymorphs in single and multi-component crystals. 
 
1.5.4. Classification of Co-crystal Polymorphs 
In single-component crystals, the key intermolecular interactions are usually 
retained in different polymorphs. For compounds with significant conformational 
changes between polymorphs, the designator conformational polymorphs is used.38 
In cases with different packing yet similar conformations of molecules, the 
polymorphs are called packing polymorphs.38 Most often both packing and 
conformational changes are observed between polymorphs.49 Co-crystals contain two 
or more molecules in the crystal so considering only packing and conformational 
changes in order to classify polymorphs would not suffice, intermolecular interaction 
contributions also need to be considered.40 These classifications are not used in the 
strictest sense and polymorphs can belong to more than one class. Nonetheless, the 
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classification system is useful in making the nature of polymorphism easy to identify 
and quantify. 
Synthon polymorphism  
Synthon polymorphs have different primary intermolecular interactions. Molecules 
that contain multiple hydrogen bonding capabilities appear to be more prone to form 
synthon polymorphs40. Co-crystals with different hydrogen bonding patterns have 
been reported. An example is the polymorphic co-crystals of 2,3,5,6-
tetramethylpyrazine and 4-hydroxybenzoic acid. Form I of this crystal contains acid–
acid dimer and hydroxyl–pyridine heterosynthon; Form II has acid–pyridine and 
hydroxyl–carbonyl heterosynthons (Figure 9).50 
                                   
Figure 9: Synthon polymorphism in 2,3,5,6-tetramethylpyrazine and 4-hydroxybenzoic acid co-
crystals.50 (a) Hydrogen bonding patterns observed in Form I of the co-crystal. (b) Hydrogen 
bonding patterns observed in Form II of the co-crystal. 
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Conformational Polymorphism 
Conformational polymorphism arises when flexible molecules are present in a co-
crystal. This tendency to form polymorphs stems from significant changes in the 
conformation of one (or more) of the molecules in the co-crystal.  According to 
Aitipamula et. al.40 conformational polymorphism is more common than synthon 
polymorphism, thus, flexible molecules are adding to the diversity of polymorphism 
in co-crystals.   
Tautomeric polymorphism 
Tautomeric polymorphs occur when different tautomers crystallize in different 
crystal forms. Tautomers that interconvert in solution or melt are considered the 
same, so co-crystals containing those different tautomers are considered 
polymorphs.40 This type of polymorphism is rare. An example of tautomeric 
polymorphism is observed in the co-crystal of piroxicam and 4-hydroxybenzoic acid, 
which has two tautomeric polymorphs.51  In the one polymorph piroxicam is present 
in its non-ionized state and in the other the zwitterionic form is present.  
Packing polymorphism 
Packing polymorphism is when the overall 3D arrangement is different in 
polymorphs. Packing polymorphism is more common in co-crystals containing 
completely rigid molecules or molecules with weak conformational flexibility.40  A 
textbook example of packing polymorphism is the 2:1 polymorphic co-crystal of 2-
aminopyrimidine and benzoic acid.52 With both molecules being rigid, the possibility 
of conformational polymorphism is low. The same intermolecular interactions are 
present in both crystals. The difference between the two polymorphs is only the 
packing. In Form I there is a herringbone packing arrangement (Figure 10a) whereas 
Form II does not contain the herringbone arrangement (Figure 10b). 
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Figure 10: Packing polymorphism observed in polymorphic co-crystal of 2-
aminopyrimidine·benzoic acid. (a). Form I of 2-aminopyrimidine·benzoic acid co-crystal. (b) 
Form II of 2-aminopyrimidine·benzoic acid co-crystal. 
 
1.6. The Cambridge Structural Database 
In supramolecular retrosynthesis the synthons which are observed in known crystal 
structures are the ones to be relied on most frequently because of the probability of 
them forming in the target supermolecule is high.13 Supramolecular synthesis is 
based on the understanding and manipulation of robust synthons; however, in order 
to know which of these synthons are indeed robust, a representative collection of 
crystal structure data is required.13 The Cambridge Structural Database (CSD)53 fulfils 
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the role of housing such data.13 The CSD is a depository for X-ray and neutron data on 
organic and organometallic crystals created by the Cambridge Crystallographic Data 
Centre. Currently, the database holds over 800 000 structures (November 2015).  
This database is the ideal place to gain an understanding of the frequency and kinds 
of polymorphism found in co-crystals. Even though not all reported organic crystal 
structures are deposited into the database, a good approximation of the propensity of 
polymorphism in small molecule organic co-crystals may still be obtained. 
 
1.7. Aims 
The goal of this project was to screen for polymorphic co-crystals from a pool of 
known co-crystals. This is important because there is a gross lack of data regarding 
polymorphism in co-crystals. Since co-crystals present a new paradigm in the realm 
of optimisation of pharmaceuticals, it is imperative that co-crystals and their 
behaviour are well understood.  
The objectives of this MSc project are to:  
 Perform a database survey; 
 Screen for polymorphs of selected co-crystals; 
 Isolate and characterize the polymorphs that are found.  
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2. The Hunt for Polymorphic Co-
Crystals 
 
2.1. Introduction 
Recent reports by Aitipumula and co-workers found that as of September 2013 there 
were 114 polymorphic co-crystals reported in the literature.40 In an earlier study,54   
the group reported that an “exhaustive” analysis of the CSD showed that the 
percentage of polymorphic co-crystals is comparable to the percentage of 
polymorphic single component crystals. In the same year (2010), Zaworotko et. al. 55 
reported a similar observation in their published database analysis. 
A database analysis of the co-crystal structures deposited in the CSD was performed. 
The analysis was performed in order to find out how many polymorphic co-crystals 
are currently in the CSD and how many of those are pharmaceutical co-crystals. 
 
2.2. Methodology 
Searches were performed in the CSD53 (version 5.36 with the November 2014, 
February 2015 and May 2015 updates) using ConQuest(version 1.17).56 Structures 
were visualised using Mercury (version 3.5).56, 57 
Binary organic co-crystals which fall into the definition mentioned in Chapter 1 were 
isolated. In order to narrow the scope of the analysis, the following restrictions were 
imposed.  
i. Organic co-crystals containing only C, H, O, N, S, F, Cl, Br, and I were targeted.  
ii. Molecules must be solid at standard temperature and pressure.  
iii. Crystals containing zwitterions were excluded. 
iv. Clathrates and inclusion complexes were excluded. 
Figure 11 shows the queries and Boolean logic used to search for hits that satisfy the 
aforementioned search parameters. Query one was used get hits that contain two 
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different compounds in the crystal. Query two ensures that the structures have at 
least one hydrogen and an oxygen atom and between five and forty carbon atoms. 
Queries two and three are used to obtain hits that contain the elements C, H, O, N, S, F, 
Cl, Br, I only. Zwitterions were excluded by searching for structures that did not 
contain any charge on any atom (query four). Due to earlier searches that yielded a 
large number of hits that contained common solvent and gas molecules but were not 
identified as solvates an additional restriction on the formula was added. None of the 
individual molecules in the structure could have fewer than five carbon atoms (query 
five). Furthermore, stray solvates were removed manually. Queries six to eight 
eliminated the hydrates, clathrates and solvates respectively.  Hits were subjected to 
additional filters that ensured that hit had: 
 3D coordinates determined; 
 no ions; 
 no powder structures; 
 not polymeric; 
 no errors. 
Crystal structures in the CSD are grouped according to chemical entities in the 
structure. A group of structures contain the same entities is assigned a ‘refcode’ 
which is made up of six letters. The individual entries are indicated by the addition of 
two numbers at the end of the refcode. Polymorphic crystal structures are placed in 
the same refcode family with a small number of assignment errors.i Polymorphs were 
isolated by searching the dataset for structures flagged as polymorphs. Additionally, 
manual analysis of refcode families and the dataset was conducted to isolate the co-
crystals that are not flagged as polymorphs. The isolated polymorphs were then 
classified according to the type of polymorphism. Duplicate structures and stray 
solvates were removed manually. 
Pharmaceutical co-crystals were identified and isolated in two ways. The first 
approach was to search the dataset for crystal structures that contained either the 
                                                        
i Two examples of this error were found for the polymorphic co-crystals of (6-methoxy-1,3-
benzothiazol-2-amine) and decanedioic acid (FEXHOH and UYAZEA) and the co-crystals of  salicylic 
acid and  4,4'-bipyridine (KONZEU and KOPKEH). 
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word “drug” or “pharmaceutical” in the crystal description. The remaining 
pharmaceuticals were identified manually be online searches for the individual 
molecules within the crystal or the common names of the molecules if given.  
24 
 
 
Figure 11: Screenshot of ConQuest showing the queries and Boolean logic used to generate the 
hit list for database survey.  
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2.3. Results 
There was a total of 2925 neutral organic co-crystals found in the CSD. There were 
400 pharmaceutical co-crystals and 239 polymorphic co-crystals within the 2925 hits 
(Figure 12).  The polymorphic co-crystals were categorized according to the type of 
polymorphism. The co-formers of the pharmaceutical co-crystals were analysed and 
grouped according to whether they were GRAS, non-GRAS or a second drug 
compound. As is true for any data survey, there may be inadvertent omissions due to 
oversight; we present our apologies to the authors of those articles. 
 
Figure 12: Plot showing the propensity of pharmaceutical co-crystal and polymorphs in co-
crystals in a CSD study of 2925 neutral organic co-crystals. 
 
2.3.1. Polymorphic Co-crystals 
How prone co-crystals are to polymorphism is a question that many groups have 
tried to address, but up to now there is insufficient data available on polymorphic co-
crystals to be able to draw a conclusion.40 This study attempts to address this by 
categorizing the currently available data on polymorphic co-crystal in order to get an 
overview of what kinds of polymorphism are prevalent in co-crystals.  
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The search performed found 239 polymorphic co-crystals. These co-crystals had an 
almost even distribution of synthon, packing and conformational polymorphism 
(Figure 13). None of the co-crystal showed tautomeric polymorphism. The case of 
piroxicam was not included due to the fact that in one of its polymorphs crystallized 
as a zwitterion.  
 
Figure 13: Plot showing percentage of co-crystals that exhibited various types of polymorphism 
in a CSD screen of 239 polymorphic co-crystals. 
 
Packing and conformational polymorphs were the two highest types of 
polymorphism. In the packing polymorphism group, all the co-crystals had similar 
intermolecular interactions and the molecules had similar conformations. The only 
change was the packing in the different polymorphs. For example, the co-crystal of 
N,N’-diacetylpiperazine and 2-hydroxybenzoic acid had O-H(carboxylic acid)···O=C(amide) 
heterosynthons between the piperazine and benzoic acid in both polymorphs.52 Also 
both molecules are relatively rigid and the conformations of the molecules in the 
polymorphs are similar. The only difference between the two polymorphs is their 
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packing, which in form I has a zigzag-like pattern (Figure 14a), and in form II has 
two-dimensional layers of each co-former (Figure 14b). 
 
Figure 14: The packing in the polymorphic co-crystals of N,N’-diacetylpiperzine and 2-
hydroxybenzoic acid.52(a)Packing diagram of form I of the co-crystal. (b) Packing diagram of 
form II of the co-crystal. 
 
As noted by Aitipamula et. al. conformational polymorphism is more common than 
synthon polymorphism,40 although the gap between the two is not large, with 32% of 
co-crystals having conformational polymorphism and 30% having synthon 
polymorphism. The flexibility of compounds such as AMG 517 and 1,2-bis(4-
pyridyl)ethane can be seen in their co-crystalline solid states, in which these 
compounds have polymorphic co-crystals which contain different conformations of 
the compound. Figure 15 shows overlays of the molecules in some co-crystals that 
exhibit conformational polymorphism.  
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Figure 15: Some examples of conformational polymorphism.58, 59 The molecules in purple are 
from form I of the different co-crystals and the molecules in blue are from form II of the 
different co-crystals. Changes in conformation are observed in the molecules on the left and 
these changes then result in the different polymorphs of the co-crystal. 
 
There were multiple co-crystals that displayed synthon polymorphism. In total 39 
pairs of co-crystals were found to be related by synthon polymorphism. One such 
example is the co-crystal of 4,4’-bipyridine and 4-hydroxybenzoic acid.60 In form I 
polymorphs there are carboxylic acid dimers which interact with the 4,4’-bipyridine 
via a hydroxy···pyridine interaction (Figure 16a). In polymorph II, the carboxylic acid 
dimer is not present and the co-crystal is sustained by a pyridine···carboxylic acid 
heterosynthon and a hydroxy···carboxylic acid interaction (Figure 16b). 
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Figure 16: Synthon polymorphism in co-crystal of 4-hydroxybenzoic acid and 4,4’-
bipyridine.60(a) Hydrogen bonding synthons observed in form I of 4-hydroxybenzoic acid∙4,4’-
bipyridine. (b) Hydrogen bonding synthons observed in form II of 4-hydroxybenzoic acid∙4,4’-
bipyridine. 
 
2.3.2. Pharmaceutical Co-crystals 
With a large amount of interest in pharmaceutical co-crystal in recent years, a survey 
of the CSD was performed in order to gauge the amount of data contributed by co-
crystals screens of API. The total number of pharmaceutical co-crystals found in the 
CSD was 400, which is 14% of the total number of neutral co-crystals. This 
percentage is very low and is most likely not a true reflection of the situation. This is 
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because many drug compounds have zwitterionic forms and many of the screens 
performed in industry are not deposited into the database.  
The types of co-formers used for the co-crystallization of these pharmaceutical co-
crystals were assessed. It was found that most of the co-formers used were non-GRAS 
compounds and only 47% (including drug-drug co-crystals) were GRAS compounds. 
It was also found that there were a significant number of drug-drug co-crystals (co-
crystals composed of two or more drug APIs) (Figure 17). Of the 400 pharmaceutical 
co-crystals, 145 were co-crystals with GRAS co-formers and 44 were drug-drug co-
crystals.  
There were 56 pharmaceutical co-crystals which were found to be polymorphic. In 
the co-crystals found in the CSD, caffeine proved to be the API with the highest 
number of polymorphic co-crystals (5). Figure 18 lists the co-formers used in the five 
polymorphic co-crystals of caffeine and also the type of polymorphism. 
 
Figure 17:  Plot showing the percentage of co-crystals that fell into different types of 
pharmaceutical co-crystal groups in a screen carried out on 400 pharmaceutical co-crystals 
found in the CSD. 
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4-Chloro-3-nitrobenzoic acid61 
Packing polymorphism 
 
Glutaric acid62 
Conformational polymorphism 
 
Citric acid63 
Conformational polymorphism 
 
Mesaconic acid64 
Packing polymorphism 
Pterostilbene 65                                          
Packing polymorphism 
 
Figure 18: The different co-formers found in the 5 polymorphic caffeine co-crystals and the 
type of polymorphism observed in each co-crystal.  
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3. Methods and Materials 
There are many methods of crystallization available to one seeking to grow crystals. 
Which methods will be successful is system dependent and as a result it is common 
place in the realm of crystal growing to try multiple methods in order to obtain the 
desired crystal structure. When screening for polymorphs it is even more so 
important to expose the system to different crystallization because this increases 
ones chances of success, for this reason, many crystallization experiments were 
performed using different conditions.  
Due  to  the  high  volume  of  experiments performed this chapter gives a brief 
overview of the key methods employed during the  study  and  a  more  detailed  
account  of  the  experiments  performed - including solvents, temperatures, and 
crystallization methods used -  is  given  in digital appendix B The different APIs and 
co-formers used in the study are listed in Table 3.           
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Table 3: List of the active pharmaceutical ingredients used in the project along with the co-
formers used for the polymorphism screen. 
Active pharmaceutical ingredient Co-formers 
Theophylline 3,4-dihydroxybenzoic acid 
3,5-dihydroxybenzoic acid 
2,5-dihydorxybenzoic acid 
2,4-dihydroxybenzoic acid 
Cinnamic acid 
Carbamazepine Cinnamic acid 
Piracetam L-Tartaric acid 
Mandelic acid 
Glutaric acid 
Citric acid 
Flufenamic acid 
Mefenamic acid 
 Tolfenamic acid. 
4-Aminopyridine 
3-Aminopyridine 
2-Aminopyridine 
2-Amino-3-bromopyridine 
2-Amino-5-bromopyridine 
2-Amino-5-chloropyrine 
2-Amino-3-hydroxypyridine 
2-Amino-3-nitropyridine 
2-Amino-5-nitropyridine 
Furosemide Caffeine 
4-Aminobenzoic acid Nicotinamide  
Isonicotinamide 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
3.1. Polymorph Screening Techniques 
The screen for polymorphs began with known pharmaceutical co-crystals.  The co-
crystals were subjected to a series of polymorph screening exercises. The polymorph 
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screens involved altering the environmental conditions of the crystallization process 
in order to encourage the growth of different polymorphs of the co-crystals.  
3.1.1. Slow Evaporation 
In this method, the API and co-former were dissolved in a solvent (or mixture of 
solvents) and the solvent was allowed to evaporate off slowly in order to induce 
crystal growth. By altering the solvent, temperature and saturation different 
polymorphs may be grown from solution. 
 
3.1.2.  Slow cooling 
In this technique, the API and co-former were dissolved in a solvent to form a 
supersaturated solution. The solution was heated up and linearly cooled to room 
temperature over a number of days. The cooling was performed in an oil bath which 
was placed on a hot plate connected to a thermocouple which adjusted the 
temperature as required in order to ensure the sample cooled down slowly.  By 
cooling the solution slowly the system was subjected to different nucleation 
environments in which different molecular assemblies could be stable long enough to 
form new polymorphs. 
 
3.1.3.  Solvent-Assisted Grinding 
In this method, the API and co-former were ground together with a few drops of 
solvent for a period of time. The grinding was performed in a pestle and mortar. The 
starting materials were ground with the drop-wise addition of various solvents. A 
mixer mill was also used for grinding experiments. The instrument used was a Retsch 
MM200 mixer mill. It was used with stainless steel canisters and two stainless steel 
balls per canister. 
3.1.4. Heterogeneous Seeding 
Matzger and co-workers66-69 have shown that using different polymers as 
heterogeneous seeds can lead to the discovery of different polymorphs of both single 
and multiple component systems. This method was employed by adding different 
kinds of polymers to saturated solutions and crystals were grown on the polymers as 
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the solvent evaporated (Figure 19). The polymers used were nylon 6/10, nylon 6/6, 
nylon 11, nylon 12 and polyethylene. 
 
Figure 19: Single crystals of 3,4-dihydroxybenzoic acid (form I) growing on a polyethylene 
bead.  
3.2. Instrumentation 
3.2.1. Single Crystal X-Ray Diffraction (SXRD) 
Single crystal x-ray diffraction (SXRD) was used to obtain the 3D structure of a 
crystalline material. The diffractometer uses a Bruker APEX II CCD area detector and 
graphite monochromated MoKα1 radiation (50kV, 30mA) to collect the diffraction 
data. The data collections were performed at -100°C.  SAINT+70 was used to perform 
the data reduction. Absorption corrections and space group assignments were done 
using SADABS71, 72 and XPREP 70respectively. 
 
Crystal structures were solved and refined using SHELXS-9773, 74 on the WinGX suite.75 
SHELXS-97 used direct methods to solve the crystal structure and refinements were 
done using full-matrix least-squares/difference Fourier techniques on F2. All non-
hydrogen atoms were refined anisotropically. All hydrogen atoms were placed in 
calculated positions with aromatic C-H = 0.95 Å, hydroxyl O-H = 0.84 Å or amine N-H 
= 0.88 Å and Uiso (H) = 1.2Ueq (C), Uiso (H) = 1.5Ueq(O) and Uiso (H) = 1.2Ueq(N). 
Diagrams were generated using ORTEP-375, PLATON 76 and DIAMOND 77. 
 
36 
 
3.2.2. Powder X-Ray Diffraction (PXRD) 
Powder X-Ray Diffraction (PXRD) patterns were collected at 293 K on a Bruker D2 
Phaser diffractometer which utilizes a sealed tube Co X-ray source (λ = 1.78897 Å), 
operating at 30 kV and 10 mA, and LynxEye PSD detector in Bragg-Brentano 
geometry. 
 
3.2.3. Differential Scanning Calorimetry (DSC) 
Differential Scanning Calorimetry (DSC) was performed on a Mettler Toledo DSC822e 
using sealed aluminium pans under air. The machine was calibrated using indium 
with a purity of 99.99%, a melting point of 156.6oC and heat of fusion 28.45 J g-1. 
Various heating and cooling programs were be used in order to gather information 
regarding the melting point, enthalpy of melting for various screening methods. 
STAR-SW 9.20 was used for instrument control and data analysis. 
 
3.2.4. Hot Stage Microscopy (HSM) 
The hot stage was used is a Kofler Hot Stage placed upon an Olympus SZ61 
microscope. This technique was used to observe phase transitions and photograph 
them.  
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4. Co-Crystals of Theophylline 
 
Theophylline (TPL) is a drug used in the treatment of respiratory diseases such 
chronic obstructive pulmonary disease and asthma.78 It is part of the xanthine family 
and is an analogue of caffeine and theobromine.78 Some co-crystals of theophylline 
have been shown to drastically enhance the properties of theophylline.62 
 
4.1. Synthon Competition in Co-crystals of Theophylline  
Theophylline has various possible hydrogen bond donors and acceptors. This opens 
it up to the possibility of various hydrogen bonding frameworks within its crystals 
and this also contributes to making theophylline polymorphic. Within the three 
polymorphs of theophylline for which crystal data are available, three of the four 
different hydrogen bonding motifs are observed (Scheme 3). In Form I 79, 80 the 
observed hydrogen bonding motif is a discrete interaction between the N-H(imidazole) 
and the O=C(urea) (Scheme 3a). Form II 80, 81 display a C(4) chain motif formed by the 
N-H(imidazole) and the N=C(imidazole) (Scheme 3b). Form IV 79, 82 is stabilised by the 
formation of a ring consisting of two N-H(imidazole)···O=C(amide) interactions (Scheme 
3c). 
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Scheme 3: Hydrogen bonding motifs observed in the three reported polymorphs of 
theophylline: (a) Form I: N-H(imidazole)···O=C(urea) heterosynthon. (b) Form II: N-
H(imidazole)···N(imidazole) heterosynthon (c) Form IV:  N-H(imidazole)···O=C(amide) dimer homosynthon.                
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
Theophylline’s preference for different hydrogen bonding motifs is also observed in 
its co-crystals. In its co-crystals with various dihydroxybenzoic acids (DHB), the API 
displays different hydrogen bonding patterns in different co-crystals. Scheme 4 
depicts all the hydrogen bonding synthons observed in the co-crystals of theophylline 
and dihydroxybenzoic acids.83  
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Scheme 4: Selected hydrogen bonding motifs observed in co-crystals of theophylline and 
several dihydroxybenzoic acids. (i) Ring motif of N-H(imidazole)···O=C(carbonyl) and O-
H(hydroxyl)···O=C(amide). (ii) O-H(carboxylic hydroxyl)···N(imidazole) (iii) O-H(hydroxyl)···N(imidazole) (iv) O-
H(hydroxyl)···O=C(amide). 
 
According to literature there were two synthons observed repeatedly in multiple 
structures: the N-H(imidazole)···O=C(amide) ring observed in Form IV of theophylline 
(Scheme 3c) and an N-H(imidazole)···O=C(carbonyl), O-H(hydroxyl)···O=C(amide) cyclic 
array(Scheme 4i).83 It is likely there is competition between these synthons during 
the formation of the co-crystals. When studying only the interactions between the API 
and co-former in TPL·DHB co-crystals (Table 4) homointeraction 3c is observed in 
60% of the structures and interaction (i) is observed in the other 40%. Bučar and co-
workers83 did a study on the synthons in hydroxybenzoic acid co-crystals of 
theophylline and also reported the same trend.  
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Table 4: Observed interactions between theophylline and various dihydroxybenzoic acid co-
formers. 
Co-former Interactions* REFCODE 
2,3-dihydroxybenzoic acid i and iii DOPNAZ83 
2,4-dihydroxybenzoic acid i and iii DOPNAD83 
2,5-dihydroxybenzoic acid ii, iv and c DUCROJ83 
3,4-dihydroxybenzoic acid ii, iv and c WOCHON78 
3,5-dihydroxybenzoic acid ii, iv and c WOCHIH78 
                                      *Numbers refer to diagrams in Scheme 4 and letters refer to Scheme 3. 
The presence of so many different synthons in co-crystals of theophylline with 
various dihydroxybenzoic acids indicates that theophylline co-crystals may be 
susceptible to synthon polymorphism. In this work, various known co-crystals of 
theophylline with different dihydroxybenzoic acids were screened for polymorphism. 
These co-crystals were chosen because of the synthon diversity noted in the co-
crystals of theophylline and the dihydroxybenzoic acids. Theophylline was used 
because it has multiple hydrogen bond donor and acceptors which could interact 
with the DHBs in different was thus leading to synthon polymorphs. Also, 
theophylline is structurally very similar to caffeine which has multiple polymorphic 
co-crystals and it was hoped theophylline would also be as prone to co-crystals 
polymorphism. Only the co-crystals of theophylline and 3,4-dihydroxybenzoic acid 
was found to be polymorphic and is reported in this work. The other failed 
polymorphism screens are reported in the digital appendix B.  
 
4.2. Polymorphic Co-Crystal of Theophylline and 3,4-
Dihydroxybenzoic acid.  
In previous studies 78, 83 a co-crystal of theophylline and 3,4-dihydroxybenzoic acid 
(3,4-DHB) was reported. In the present work the co-crystal (Form I) was 
resynthesized along with a novel polymorph of the co-crystal (Form II).  
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4.2.1. Experimental  
Synthesis of diffraction quality crystals of the previously known co-crystal 1 was 
achieved by slow evaporation from a solution of 1:4 methanol/chloroform (5 ml) and 
equimolar amounts of theophylline (0.0300 g)  and 3,4-DHB (0.0261 g). Bulk samples 
were prepared by solvent-assisted grinding (with acetonitrile) using stainless steel 
jar in a Retsch MM200 mixer mill at 25Hz for 10 mins. 
Form II was initially prepared by slow evaporation at ambient temperatures from a 
solution of 1:4 methanol/chloroform (5 ml) and equimolar amounts of theophylline 
(0.0298 g) and 3,4-DHB (0.0245 g). This yielded diffraction quality crystals. However, 
subsequent attempts to resynthesize II using the aforementioned method resulted in 
I. The new form essentially disappeared for a year until it was synthesized again 
(reproducibly) via two methods. The first method is crystallization from solution (1:4 
methanol/chloroform) at 80°C. The second method is crystallization in ethanol in the 
presence of polyethylene at ambient temperatures. Once II has formed it is stable at 
ambient temperatures.  
Both forms were characterised using PXRD, SXRD and thermal techniques. 
Crystallographic data pertaining to the two polymorphs is summarised in Table 5. 
Bulk formation of the co-crystals was confirmed using PXRD (Supporting 
information: Figures S1 and S2)  
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Table 5: Crystallographic Data for Forms I and II of (TPL)·(3,4-DHB) 
Polymorph I II 
Chemical formula C14H14N4O6 C14H14N4O6 
Mr 334.29 334.29 
Crystal system, space group Triclinic, P1̅ Orthorhombic, Pbca 
Temperature (K) 293 173 
a, b, c (Å) 
8.0998 (3), 8.6294 (3), 11.6014 
(4) 
6.7095 (3), 13.7764 (6), 
30.7205 (15) 
α, β, γ (°) 
102.915 (2), 105.069 (2), 
105.647 (2) 
90.00, 90.00, 90.00 
V (Å3) 715.41 (4) 2839.6 (2) 
Z 2 8 
Radiation type Mo Kα Mo Kα 
µ (mm−1) 0.12 0.13 
Crystal size (mm) 0.71 × 0.37 × 0.34 0.39 × 0.12 × 0.07 
Data collection 
Diffractometer 
Bruker APEX-II CCD  
diffractometer 
Bruker APEX-II CCD  
diffractometer 
Absorption correction Multi-scan  SADABS 72 Multi-scan  SADABS 72 
No. of measured, independent 
and 
observed [I > 2σ(I)] reflections 
8285, 3450, 2862 16504, 3518, 2067 
Rint 0.043 0.078 
(sin θ/λ)max (Å−1) 0.661 0.667 
Refinement 
R[F2 > 2σ(F2)], wR(F2), S 0.051, 0.163, 1.15 0.049, 0.164, 0.84 
No. of reflections 3450 3518 
No. of parameters 218 219 
No. of restraints 0 0 
H-atom treatment 
H atoms treated by constrained 
refinement 
H atoms treated by constrained 
refinement 
Δρmax, Δρmin (e Å−3) 0.88, −0.39 0.22, −0.24 
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4.2.2. Crystal Structures of the polymorphs of (TPL)·(3,4-DHB) 
The asymmetric units of the two polymorphs both contain one molecule of TPL and 
one molecule of 3,4-DHB as seen in Figure 20.  
 
Figure 20: Asymmetric units of Forms I and II of the (TPL)·(3,4-DHB) co-crystal. The atomic 
numbering in the crystal structures is shown along with the non-symmetry related hydrogen 
bonding (indicated by the red dashed lines).  
 
As reported by Sarma et. al.78 and Bučar, et. al.83 the crystal structure of I contains the 
robust carboxylic acid dimer along with the TPL dimer formed by the N-
H(imidazole)···O=C(amide) heterosynthon. Also, in the structure are other interactions 
between the acid and the API. There is an O-H···O=C(urea) heterosynthon and a O-
H···N(imidazole) heterosynthon. These interactions are represented by the red dashed 
bonds in Figure 21. This hydrogen bonding scaffolding leads to the formation of 
planar sheets within the co-crystal.  
Form II has different motifs in the crystal. The robust TPL and carboxylic acid dimers 
are not observed in this form. Instead, there is a cyclic array formed between the 
carboxylic acid and the TPL via an O-H(carboxylic acid)···O=C(amide) and N-
H(imidazole)···O=C(carboxylic acid) interactions. This means that the polymorphs of 
(TPL)·(3,4-DHB) are synthon polymorphs. For this co-crystal, the targeted synthon 
II 
I 
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polymorph was indeed formed.  Form II also displays different packing; unlike I, it 
does not crystallise in 2D planar sheet instead the molecules pack in corrugated 
sheets (Figure 21). 
 
Figure 21: Hydrogen bonding patterns in the polymorphs of the co-crystal (Theophylline)·(3,4-
dihydroxybenzoic acid). The red dashed lines represent hydrogen bonds and hydrogen atoms 
were excluded for clarity.(a) Hydrogen bonding in form I of the co-crystal. (b)Packing in I. (c). 
Hydrogen bonding in form II of the co-crystal. (d) Packing in II. 
 
4.2.3. Thermal Studies of (TPL)·(3,4-DHB) Polymorphs. 
Thermal characterization of polymorphs is one way to categorise polymorphs. Thus 
far the Roman numerals used to denote the polymorphs have been used without 
clarification. The previously known form has been called Form I because it is more 
thermally stable than the novel Form II. Upon heating at 10°/min, I undergoes no 
phase transitions or changes of any kind until it melts at a temperature of 250.5°C 
(Table 6). The DSC trace (Figure 22) also shows that soon after this melting point the 
co-crystal decomposes.  
(a) (b) 
(d) 
(c) 
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Figure 22: DSC traces of the polymorphs of (TPL)·(3,4-DHB). The red trace shows the heating of 
Form I and the purple trace shows the response of Form II to heating and a phase transition 
(from II to I) at 63.2°C is observed.  
 
Table 6: Temperatures of the melting and transition endotherms. 
 Melting endotherm Transition endotherm 
 Tonset °C Tpeak °C Tonset °C Tpeak °C 
I 249.5 250.5 N/A N/A 
II 249.5 249.9 59.9 63.2 
 
Upon heating II transforms into I over a long temperature range. Due to this slow 
transformation, the DSC trace of Form II was obtained at a faster heating rate than 
the DSC experiment of I at 20°/min.  With the faster heating rate, the transition 
temperature of II to I was observed at 63.2°C.  In the DSC experiments once II had 
transformed into I there are no more transitions observed until I melts at 249.9°C 
and decomposes soon thereafter. The decomposition is seen in both DSC traces of I 
and II as an endothermic hump soon after the sharp melting point. 
The phase transition is not reversible. This was observed by heating the II crystals 
high enough to induce the phase transition but not high enough to melt the resulting I 
crystals. Upon cooling I crystals that formed and did not convert into II, thus, 
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indicating that the phase transition is not reversible. A cooling run was performed on 
the melted crystals of II (that transformed into I) and a phase transition from I to II 
was not observed in the trace. 
 
Figure 23:Thermal analysis of the different polymorphs of theophylline∙3,4-dihydroxybenzoic 
acid performed on a hotstage. (a) Block morphology of form I of the co-crystal. (b) Needle 
morphology of form II of the co-crystal. (c) Heating of Form II lead to needles darkening as 
phase transition occurs. (d). Form I blocks formed from the form II needles upon further 
heating. 
 
The transition was also monitored using HSM. The polymorphs of (TPL)·(3,4-DHB) 
crystallized in two different morphologies. Form I crystallized in large blocks (Figure 
23a) and II produced thin needles (Figure 23b). When the needles of II were heated a 
slow phase transition occurred over a long temperature range (105°C - 216°C).  As 
the transformation began the clear needles of II (Figure 23a) darkened (Figure 23c) 
(a) (b) 
(c) 
(d) 
I 
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and with more heating blocks of I visibly grew from the needles of II (Figure 23d). 
The transition is not a single crystal to single crystal transformation.  
The Burger-Ramberger rules were applied in order to properly classify the 
relationship between the polymorphs as either enantiotropic or monotropic. The 
relationship between these two synthon polymorphs is enantiotropic because the 
phase transition is endothermic.38  
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5. Co-crystal of Carbamazepine 
 
5.1. Introduction 
Pharmaceutically active compound carbamazepine (5H-dibenz[b,f]azepine-5-
carboxamide) has well-documented antiepileptic and analgesic behaviour.84 
Carbamazepine is also known to form at least four different polymorphs as well as an 
expanding number of hydrates, solvates, and co-crystals.85 Carbamazepine has a rigid 
molecular framework which means that structural changes in its multi-component 
crystals is mostly due to intermolecular changes rather than intramolecular changes. 
This makes it an ideal candidate for a synthon polymorphism study. 
In the various polymorphs of pure carbamazepine, there is a dimer-forming 
homosynthon (Scheme 5). This dimer is also present in many of the carbamazepine 
co-crystals salts and other crystalline forms.85 This dimer is observed in 33% of the 
156 carbamazepine co-crystals studied by Childs et. al.85 The co-former in those 156 
co-crystals all contained a carboxylic acid moiety. This indicates that the dimer is 
very robust but also that in some case the dimer can be broken. 
 
Scheme 5: Carbamazepine dimer forming urea···urea homosynthon. 
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In the case of polymorphic co-crystal carbamazepine·4-hydroxybenzoic acid,85 the 
dimer is present in form I of the co-crystal (Figure 24a) and is not formed in the other 
polymorph. Form II possess a C22(6) hydroxyl···carboxamide chain that links the API 
to the carboxylic acid (Figure 24b).   
 
Figure 24: (a) Carbamazepine dimer observed in carbamazepine·4-hydroxybenzoicacid form I 
co-crystals. (b) Heterosynthon observed in carbamazepine·4-hydroxybenzoicacid  form II co-
crystals. 85 
50 
 
In previous experimental studies25, 86 it was indicated that carbamazepine does form 
co-crystals with cinnamic acid. This co-crystal was reported as a powder and the 
possible synthon framework holding the co-crystal together was predicted using 3D 
modelling by Moradiya and co-workers (Figure 25).86 It predicted that the co-crystal 
of carbamazepine and cinnamic acid has an R22(8) interaction between the carboxylic 
acid of cinnamic acid and the amide of carbamazepine. In this work, we attempted to 
grow the reported co-crystal in order to know what synthons are present in this co-
crystal as well as to possibly grow the polymorph of that co-crystal. 
 
Figure 25: Intermolecular interactions of the carbamazepine∙cinnamic acid co-crystal that were 
predicted by Moridiya et al. (2014). Picture taken from ref 86. 
 
5.2. Co-crystal: Carbamazepine●Cinnamic acid 
5.2.1. Experimental 
` 
Scheme 6: Carbamazepine and Cinnamic acid. 
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Anhydrous carbamazepine form III was obtained from Sigma-Aldrich and cinnamic 
acid (form II) was obtained from the British Drug House. Both chemicals were 
characterised by PXRD. The co-crystal was synthesized by forming a 1:1 slurry of 
carbamazepine (0.0199 g) and cinnamic acid (0.0123 g) in ethyl acetate (0.1 ml). The 
slurry was sonicated in a sonic bath at 30°C for 17 hrs.  Diffraction quality crystals 
were formed in the bath and were stored in the fridge upon removal from the bath. 
The data collection and refinement details are tabulated in Table 7. Bulk formation of 
the crystal was confirmed using PXRD.   
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Table 7:   Crystallographic data for (carbamazepine)·(cinnamic acid) 
Crystal data 
Chemical formula C15H12N2O·C9H8O2 
Mr 384.42 
Crystal system, space group Monoclinic, P21/c 
Temperature (K) 173 
a, b, c (Å) 15.2149 (5), 5.4351 (2), 23.5139 (10) 
β (°) 95.488 (2) 
V (Å3) 1935.56 (13) 
Z 4 
Radiation type Mo Kα 
µ (mm−1) 0.09 
Crystal size (mm) 0.33 × 0.18 × 0.16 
Data collection 
Diffractometer APEX-II CCD 
Absorption correction Multi-scan SADABS72 
No. of measured, independent and 
observed [I > 2σ(I)] reflections 
18633, 4670, 3000 
Rint 0.059 
(sin θ/λ)max (Å−1) 0.661 
Refinement 
R[F2 > 2σ(F2)], wR(F2), S 0.048, 0.152, 1.07 
No. of reflections 4670 
No. of parameters 263 
No. of restraints 0 
H-atom treatment H-atom parameters constrained 
Δρmax, Δρmin (e Å−3) 0.21, −0.28 
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5.2.2. Powder Analysis  
The co-crystal of carbamazepine and cinnamic acid was obtained successfully, and 
visual inspection of the calculated and measured PXRD data was used to confirm bulk 
formation of the co-crystal (Figure 26). The calculated pattern was generated using 
the single crystal data in Mercury.56, 57 The match in patterns confirms that the bulk 
material is the same as the single crystal that was analysed. 
 
Figure 26: PXRD patterns of the carbamazepine∙cinnamic acid co-crystal synthesized in this 
work: (a) Measured powder pattern of the co-crystal (measured using cobalt radiation). (b) 
Calculated powder pattern of carbamazepine·cinnamic acid co-crystal using cobalt radiation. 
 
The PXRD patterns generated by Shayanfar et. al.25 and Moradiya et. al.86 were 
obtained using copper radiation; the pattern that was measured in this work was 
obtained using cobalt radiation. This being the case the measured pattern could not 
be directly compared to the patterns in literature. To confirm that the co-crystal 
formed is the same as the one reported in the literature, the literature patterns were 
compared to a pattern that was calculated from single crystal data using copper 
radiation as the source in Mercury (Figure 27).56, 57 This could be done because single 
crystal was shown to be that same as the bulk material. Visual inspection of the 
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patterns confirmed that the synthesized co-crystal was the co-crystal reported by 
Shayanfar et. al.25 and Moradiya et.al.86 
 
 
 
Figure 27: Powder patterns of the carbamazepine·cinnamic acid co-crystal taken from different 
sources: (a) Carbamazepine·cinnamic acid co-crystal powder pattern taken from ref  25. (b) 
Carbamazepine·cinnamic acid co-crystal powder pattern taken from ref 88. (c) Calculated 
powder pattern of carbamazepine·cinnamic acid co-crystal using copper radiation.  
 
5.2.3. Thermal Analysis 
Thermal analysis by differential scanning calorimetry further confirmed the 
formation of the co-crystal. The average melting point, calculated using three DSC 
thermograms is 143.7°C. This melting point is different from the melting points of 
carbamazepine (191-192°C) and cinnamic acid (132-135°C). The melting point 
(a) 
(b) 
(c) 
5 10 15 20 25 30 35 40
2θ 
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reported in the literature are 144°C25 and 143.1°C86. This provides further 
confirmation that the co-crystal formed is the one reported in the two studies. Figure 
28 shows a representative DSC thermogram of the carbamazepine∙cinnamic acid co-
crystal. This DSC trace is not flat because the crystals sublime as they get heated up. 
The melting endotherm in this trace was at 142.5°C. 
 
Figure 28: DSC thermogram of co-crystal of cinnamic acid and carbamazepine.  
 
5.2.4. Structural Analysis 
The asymmetric unit cell of the co-crystal contains a carbamazepine molecule and 
one cinnamic acid molecule and is shown in Figure 29.  
 
Figure 29: The asymmetric unit of the co-crystal with the displacement ellipsoid drawn at 50% 
probability level. 
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In the co-crystal two molecules of carbamazepine form a dimer across an inversion 
centre via an R22(8) urea homosynthon, as seen in Figure 30. This dimer is observed 
in many of the co-crystals of carbamazepine and in its four polymorphs.85 The 
cinnamic acid molecules interact with carbamazepine to form an R44(16) ring. This is 
achieved with two sets of O-H(carboxylic acid)···O=C(urea) and N-H(urea)···O=C(carboxylic acid) 
heterosynthon interactions. These intermolecular interactions do not correspond 
with the ones predicted by Moradiya et al. (2014).86 The co-crystal of carbamazepine 
and cinnamic acid was shown to be sustained by different  synthons than the ones 
predicted in the literature. The predicted synthon may possibly be obtained using 
different crystallization techniques and environments.  
 
 
 Figure 30: Hydrogen bonding interactions in carbamazepine·cinnamic acid. 
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6. Concluding Remarks 
Polymorphism in single component crystals is a phenomenon that has been 
extensively investigated, and it is now gaining interest in multiple component 
crystals. Polymorphism in co-crystals has been the subject of a several studies and 
recently more polymorphic co-crystals have been reported. 
 
6.1. Remarks on the data mining  
The quantity of polymorphic co-crystals in the CSD was investigated and 239 
polymorphic co-crystals were obtained. This is only 8% of the 2925 co-crystals that 
were isolated. When compared with the fact that approximately 50% of the single 
component crystals that are screened for polymorphism are found to be 
polymorphic, this makes it seem like co-crystallization decreases the polymorphic 
potential of co-crystals. However, since the number of targeted single component 
polymorphic screens is much larger than that of purposeful polymorphic screens of 
multi-component systems, this results in a biased view 
The polymorphs isolated from the CSD were classified by the type of polymorphism. 
Packing polymorphism was found to be the most prevalent type of polymorphism, 
followed closely by conformational polymorphism. As in single component crystals, 
the flexibility of the molecules in the co-crystal seems to play a notable role in the 
polymorphism of the co-crystal. This is suggested by the high number of 
conformational polymorphs observed. Even in co-crystals containing rigid molecules, 
like caffeine, the use of a flexible co-former opened up the possibility of conformation 
polymorphism which is not present in the crystals of the pure rigid molecules. This 
implies that one could make polymorphic co-crystals by selecting co-formers of high 
flexibility. 
 Tautomeric polymorphs were not observed; this could be a result of excluding 
zwitterions from the search parameters. A significant number of synthon polymorphs 
were found and analysis of the types of synthons that are prevalent in these co-
crystals may aid targeted attempts to form synthon polymorphs.  
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 Future database searches could provide a better overview of the current state of 
polymorphism in co-crystals. The many search restrictions that this work was 
subjected to makes it a narrow view of the big picture. The inclusion of salts and 
ternary co-crystals may provide better information on the nature of polymorphism in 
multi-component systems. Since salt formation is driven by strong ionic interactions, 
the effects of weaker interactions on the packing and polymorphism of the salts could 
give insight to the role of weaker intermolecular interaction in the formation of the 
crystal structure.  
The introduction of more molecules into a crystal structure may help or hinder the 
crystals ability to form polymorphs. At the present moment there is no data to sway 
the argument in any particular direction. A database analysis that includes co-crystals 
with more than two components could shed a little bit of light on the subject, if the 
co-crystals were studied along with their corresponding counterparts which have 
lower number of components. This could also give insight into the potential 
hierarchies of competitive intermolecular interactions.   
 
6.2. Targeted attempts to form synthon polymorphs 
The addition of extra intermolecular interactions that inherently comes with co-
crystallization increases the chances of observing synthon polymorphism. Even 
though these may be theoretically possible there is no guarantee that they will occur.  
6.2.1. Theophylline co-crystals 
The presence of multiple hydrogen bond donors and acceptors in theophylline makes 
the formation of synthon polymorphs of this API possible. Theophylline shows 
synthon polymorphism in its single-component and multi-component states. Synthon 
polymorphism was observed in the 1:1 co-crystal of theophylline and 3,4-
dihydroxybenzoic acid. The polymorphs of the co-crystal were found to be 
enantiotropically related due to the endothermic transition.  
Future studies of the relative stability of these co-crystals can be carried out with 
slurry experiments at different temperatures. This work shows that targeted synthon 
polymorphism can be achieved. Further investigation of other theophylline co-
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crystals with dihydroxybenzoic acids may also prove to contain the same type of 
synthon polymorphism. 
6.2.2. Carbamazepine co-crystals 
Carbamazepine has many known co-crystals and it has been shown that the 
carbamazepine homodimer can be interrupted by carboxylic acid moieties. Future 
work into screening of synthon polymorphism in carbamazepine∙carboxylic acid 
systems may yet prove successful. This kind of work could provide an understanding 
of the conditions that lead to co-crystal polymorphism for carbamazepine at the very 
least.  
There is ample room for investigation in the realm of polymorphism in multi-
component systems and with there being approximately 3000 neutral organic co-
crystals in a database with over 800000 (and counting) crystal structures, it is clear 
that there is not enough data on these type of molecules. Thus, it would be premature 
and very difficult to obtain a one size fits all summation of the state of polymorphism 
in co-crystals.  
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1.1. Supporting information for TPL 3,4DHB polymorphs 
1.2.1. Powder diffraction patterns of Form I and II of TPL·3,4-DHB 
The calculated pattern of form I (figure S31) is shifted slightly to the left since, the 
single crystal data and powder data were collected at different temperatures. 
 
Figure S31: PXRD of TPL·3,4-DHB form I compared to PXRD of single crystal structure 
determination of TPL·3,4-DHB form. The experimental pattern was calculated at room 
temperature and the calculated pattern at 173 K. 
 
Figure S32: PXRD of TPL·3,4-DHB form II compared to PXRD of single crystal structure 
determination of TPL·3,4-DHB form. The experimental pattern was calculated at room 
temperature and the calculated pattern at 173 K  
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